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a  b  s  t  r  a  c  t
Hypertrophic  cardiomyopathy  (HCM)  patients  often  develop  subendocardial  ischemia  in  the  left  ven-
tricle  without  atherosclerotic  coronary  stenosis.  Myocardial  ischemia  plays  an  important  role  in  the
pathophysiology  of HCM,  but diagnostic  techniques  for  the detection  of  subendocardial  ischemia  have
not  been  widely  available.  We  developed  speciﬁc  techniques  to quantify  subendocardial  ischemia  onvailable online 20 November 2013
eywords:
ardiomyopathies
ypertrophic
schemia
stress  scintigraphy,  and  have  compared  the results  with  various  clinical  features  in patients  with  HCM.
This  article  reviews  our understanding  of  subendocardial  ischemia  in  HCM  based  on more  than  20 years
of  experience.
© 2013  Japanese  College  of Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.ubendocardium
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ase presentation
A 61-year-old man  presents with chest pain on exertion. On
xamination, physical signs are normal without heart murmur. An
tomography angiography, and unique ﬁndings on myocardial per-
fusion scintigraphy (Fig. 1). How should this case be managed?lectrocardiogram shows marked left ventricular (LV) hypertrophy
n the absence of a history of hypertension. Imaging modali-
ies show asymmetric septal hypertrophy on magnetic resonance
maging, no provokable LV outﬂow tract obstruction on echocar-
iography, no atherosclerotic stenosis on coronary computed
∗ Corresponding author at: Department of Cardiology, Matsushita Memorial
ospital,  Sotojima 5-55, Moriguchi, Osaka 570-8540, Japan. Tel.: +81 66992 1231;
ax: +81 66992 4845.
E-mail address: js-k@wf6.so-net.ne.jp (T. Kawasaki).
914-5087/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2013.10.005Background
HCM is an entity ﬁrst described clinically in 1957 by Brock [1],
followed pathologically the next year by Teare [2]. In the mid-
1970s, the assessment of myocardial perfusion with thallium-201
was introduced to patients with HCM, showing regional myocardial
hypoperfusion in the absence of epicardial coronary artery disease
[3,4]. In 1987, O’Gara et al. [5] demonstrated transient LV cavity
dilation on thallium-201 obtained immediately after cessation of
maximal treadmill exercise in HCM patients with normal coronary
arteries. This scintigraphic abnormality was reported by Udelson
vier Ltd. All rights reserved.
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Fig. 1. Representative case of subendocardial ischemia in hypertrophic cardiomyopathy. Cardiac magnetic resonance shows asymmetric septal hypertrophy (Panel A, short-
axis;  Panel B, long-axis) in a 61-year-old man  with chest pain on exertion. Coronary computed tomography angiography shows no atherosclerotic stenosis in the left
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oescending coronary artery (Panel C), the left circumﬂex coronary artery (Panel D), a
s  apparent on short-axis slices of thallium-201 scintigraphy after exercise (Panel F)
schemia.
t al. in 1989 to occur without any signiﬁcant changes in the LV
avity volume before and after exercise [6]. Moreover, in 1991, Can-
on et al. [7] showed the association of the unique scintigraphic
ndings with myocardial lactate abnormalities. Thus, transient LV
avity dilation on stress scintigraphy in HCM patients without coro-
ary stenosis, for example, as shown in Fig. 1, has been considered
o reﬂect subendocardial ischemia in the LV. Myocardial ischemia
lays an important role in the pathophysiology of HCM [8,9], but
uantitative diagnostic techniques for the detection of subendocar-
ial ischemia have not been fully understood in clinical practice.
In 1990, we developed speciﬁc software to quantify transient
V cavity dilation or subendocardial ischemia based on stress
cintigraphy in patients with HCM [10]. Brieﬂy, in a thallium-201
hort-axis slice of the mid-LV, 36 radii were generated at 10-degree
ntervals from the center of the image. An area surrounded by
6 points, each displaying the maximum count on each radius, was
alculated automatically in the stress and rest images, and suben-
ocardial ischemia was assessed on the basis of the ratio of the
urface area during stress to that at rest. The ratio that we calcu-
ated was not based on a genuine LV cavity during stress to that
t rest, but the ratio could be an index of subendocardial ischemia
ecause subendocardial ischemia causes the maximum count on
he radius to move outward. This speculation is supported by our
ndings that LV end-diastolic volume did not change 10 min  after
xercise and at rest as assessed by radionuclide ventriculography
10]. We  had applied this technique to HCM patients in the clinical
etting for almost 10 years [11]. In 2000, we modiﬁed our method
or a more accurate analysis; the LV was divided into 15 short-axis
lices and 100 radii were generated at 3.6-degree intervals from
he center of each image, as shown in Fig. 2. An area surrounded by
00 points each displaying the maximum count on each radius was
alculated automatically in the stress and rest images. Subendocar-
ial ischemia was considered present if the stress to rest ratio in
he sum of the 15 surface areas was greater than the mean plus 2
tandard deviations in normal subjects (i.e. 1.07) [12]. These pro-
rams that we previously developed and appropriately modiﬁed
ave enabled us to compare subendocardial ischemia with vari-
us clinical features in patients with HCM. This article reviews oure right coronary artery (Panel E). Notably, exercise-induced transient cavity dilation
ared with at rest (Panel G), features consistent with left ventricular subendocardial
understanding of subendocardial ischemia in HCM based on more
than 20 years of experience.
Epidemiology
Approximately one-third to one-half of patients with HCM
developed subendocardial ischemia during stress testing without
atherosclerotic coronary stenosis in our cohorts [10–12] and other
populations [5,7]. In our different groups of patients with HCM,
chest symptoms were more frequently observed in HCM patients
with subendocardial ischemia than in patients without subendo-
cardial ischemia (67% versus 31%, p = 0.01 [10] and 65% versus 25%,
p = 0.01 [13]), but subendocardial ischemia was not associated with
age, gender, body mass index, a previous history of syncope, or
family history of HCM, or of unexpected sudden death [12].
Electrocardiography
We  examined the details of electrocardiographic ﬁndings during
exercise testing with scintigraphy in 48 HCM patients, and found
that resting ST-segment depression, deﬁned as >0.1 mV  in depth
except for aVR, as shown in Fig. 3A, was  an independent predictor
for the presence of subendocardial ischemia [12]. In brief, the inci-
dence of resting ST-segment depression was  11 patients of 17 with
subendocardial ischemia and 9 of 31 patients without subendo-
cardial ischemia (p = 0.02). The diagnostic performance of the total
number of leads with resting ST-segment depression ≥3 was  a sen-
sitivity of 65%, a speciﬁcity of 90%, an accuracy of 81%, a positive
predictive value of 79%, and a negative predictive value of 82%. On
the other hand, ST-segment depression during exercise was not
a reliable marker of subendocardial ischemia, ﬁndings consistent
with previous reports [5,7]. Repetitive ischemia in the subendo-
cardium is a possible cause of resting ST-segment depression in
HCM patients with subendocardial ischemia, as in patients with
chronic ischemic heart disease [14].
Moreover, in 29 HCM patients with asymmetric septal hyper-
trophy, we  found that 5 of 15 patients with diffuse subendocardial
ischemia had small q waves in leads V5 and V6 (i.e. septal q waves)
T. Kawasaki, H. Sugihara / Journal of Cardiology 63 (2014) 89–94 91
Fig. 2. Quantitative assessment for subendocardial ischemia in hypertrophic cardiomyopathy. The left ventricle on technetium-99m tetrofosmin myocardial scintigraphy is
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divided into 15 short-axis slices (Panel A). Panel B shows the close-up view of the la
rawn  at 3.6-degree intervals from the center of the left ventricle; a white circle is 
t rest, all the 5 showing a decrease in amplitude during exercise,
s shown in Fig. 3B. Of 14 HCM patients with no subendocardial
schemia, 7 had a septal q wave at rest, 4 of them showing a
ecrease in amplitude during exercise. Decreased amplitude of
he sum of septal q waves in leads V5 and V6 during exercise
ielded a sensitivity of 100%, a speciﬁcity of 43%, an accuracy of
7%, a positive predictive value of 56%, and a negative predictive
alue of 100% for the detection of subendocardial ischemia [15].
eptal q waves are considered to reﬂect the rightward-directed
epolarization through the ventricular septum [16]. The response
f septal q waves to exercise has been reported to be a reliable
arker of septal ischemia in patients with ischemic heart disease
17]. Other electrocardiographic ﬁndings at rest and the responses
o exercise, for example, abnormal Q wave, ST-segment elevation,
-wave inversion, and R-wave amplitude were not associated with
ubendocardial ischemia in our HCM patients [12,18].
utonomic function
Patients with HCM often fail to increase blood pressure dur-
ng exercise [19,20], known as abnormal blood pressure response,
hich has been reported to be associated with subendocardial
schemia [21]. Vagal nerves mediate inhibitory responses in the
ardiovascular system. Thus, we examined vagal response to
ubendocardial ischemia in relation to abnormal blood pressure
esponse; vagal modulation was assessed by means of the per-
entage change in the high-frequency component of heart rate
ariability from 5 min  before to after exercise using commer-
ially available software (MemCalc/Tarawa, GMS  Co. Ltd., Tokyo,
apan) [22]. We  found that vagal enhancement after exercise
as higher in HCM patients with subendocardial ischemia than
n those without it. Furthermore, HCM patients with abnormal
lood pressure response, deﬁned as a failure to exhibit an increase
25 mmHg  during exercise, were characterized by higher vagal
nhancement after exercise. These ﬁndings suggest that suben-
ocardial ischemia provoked vagal enhancement in patients with
CM, leading to the development of an abnormal blood pressure
esponse to exercise. The fact that vagal nerves are predominantly
istributed in the LV subendocardium [23–25] may  explain thert-axis slice (surrounded by a white line on Panel A) under analysis; white radii are
sed of black points located on the maximum count of each radius.
mechanism linking subendocardial ischemia to vagal enhancement
[26].
Echocardiography
In our HCM cohort, patients with and without subendocardial
ischemia did not differ signiﬁcantly with respect to conventional
echocardiographic ﬁndings including LV fractional shortening, ven-
tricular septum thickness, E/A, or deceleration time of E, but left
atrial end-systolic diameter was  larger in patients with subendo-
cardial ischemia than in patients without subendocardial ischemia
(43 ± 5 mm versus 40 ± 3 mm,  p = 0.04 [13] or 42 ± 5 mm versus
38 ± 3 mm,  p = 0.03 [27]). Enlarged left atrial diameter associated
with subendocardial ischemia may  be supported by elevated LV ﬁll-
ing pressure in HCM patients with subendocardial ischemia [6,7].
However, the diagnostic value of left atrial diameter does not seem
to be of clinical use because of the considerable overlap in the values
between HCM patients with and without subendocardial ischemia.
In our study using ultrasonic tissue characterization in HCM
patients with asymmetric septal hypertrophy, as shown in Fig. 3C,
the ratio of cyclic variation of integrated backscatter in the right
halves to the left halves was signiﬁcantly higher in patients with
subendocardial ischemia than in those without it [13]. In receiver
operator characteristic curve analysis, a ratio of cyclic variation of
integrated backscatter in the right halves to the left halves >1.0
had good predictive value in detecting subendocardial ischemia: a
sensitivity of 80%, a speciﬁcity of 71%, an accuracy of 76%, a posi-
tive predictive value of 80%, and a negative predictive value of 71%.
We may  safely consider that repetitive subendocardial ischemia
causes reduction in cyclic variation of integrated backscatter in the
left halves of the ventricular septum in HCM, as in patients with
chronic stable ischemic heart disease [28].
ScintigraphyWe examined the hypothesis that volumetric variables obtained
by technetium-99m tetrofosmin gated single-photon emission
computed tomography using commercially available software
(QGS Software, Cedars-Sinai Medical Center, Los Angeles, CA, USA)
92 T. Kawasaki, H. Sugihara / Journal of Cardiology 63 (2014) 89–94
Fig. 3. Diagnostic techniques for subendocardial ischemia in hypertrophic cardiomyopathy. The keys to detecting subendocardial ischemia in hypertrophic cardiomyopathy
are  ST-segment depression on resting electrocardiography (Panel A), a decreased septal q wave during exercise electrocardiography (Panel B, arrow), decreased cyclic
variation of integrated backscatter in the left half of the ventricular septum on ultrasonic tissue characterization (Panel C), a superﬁcially increased left ventricular volume
a nd po
h el E).
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ofter  exercise on gated single-photon emission computed tomography (Panel D), a
alf  of the ventricular septum on positron emission tomography after exercise (Pan
re useful in detecting subendocardial ischemia in HCM patients
ith asymmetric septal hypertrophy and a maximum wall thick-
ess of ≤20 mm [27]. This patient selection was based on the results
f a study of cardiac phantom modifying HCM with asymmetric
eptal hypertrophy [29], which showed that the difference between
he LV volume obtained by QGS software and the actual LV volume
as within 3% when the maximum wall thickness was ≤20 mm,  but
therwise the difference was ≥8%. In our selected population [27],
V end-systolic and end-diastolic volumes after exercise, compared
ith at rest, were higher in HCM patients with subendocardial
schemia than in those without it, as shown in Fig. 3D. Consid-
ring no signiﬁcant changes in true LV cavity volumes assessed
y radionuclide ventriculography before and after exercise [6,10],
e speculate that the superﬁcial increase in LV volumes on QGS
oftware in HCM patients with subendocardial ischemia was a
esult of decreased tracer accumulation in the LV subendocardium
fter exercise. The receiver operator characteristic curve analysis of
xercise-induced percentage changes in LV end-systolic volume for
he detection of subendocardial ischemia showed that the optimal
ut-off was 17%, with a sensitivity of 89%, a speciﬁcity of 82%, an
ccuracy of 82%, a positive predictive value of 73%, and a negative
redictive value of 93%.The indexes for regional myocardial ischemia (i.e. summed
tress score and summed difference score) were signiﬁcantly
igher in patients with subendocardial ischemia than in those with-
ut it [12,27]. These ﬁndings indicate that our method for thessibly 18F-ﬂuorodeoxyglucose accumulation predominantly distributed in the left
detection of subendocardial ischemia is not completely indepen-
dent of regional myocardial ischemia. This limitation is, however,
inevitable because subendocardial ischemia often occurs accompa-
nied by regional myocardial ischemia in most patients with HCM
[5–7].
Positron emission tomography
A technique that combines exercise testing and positron emis-
sion tomography with 18F-ﬂuorodeoxyglucose has been reported
to provide direct imaging of myocardial ischemia in patients
with ischemic heart disease [30]. Similarly, we showed that the
technique was  available in detecting subendocardial ischemia
in a patient with HCM, as shown in Fig. 3E [31]. Brieﬂy, 18F-
ﬂuorodeoxyglucose was injected intravenously 3 min  after peak
exercise, and positron emission tomography/computed tomogra-
phy of the LV was  acquired 50 min  after the injection, showing
tracer accumulation predominantly in the left half of the ventricu-
lar septum in a patient with nonobstructive HCM with asymmetric
septal hypertrophy. We applied this technique to 6 nonobstruc-
tive HCM patients with asymmetric septal hypertrophy, and found
that 3 of 6 showed apparent uptake of 18F-ﬂuorodeoxyglucose pre-
dominantly in the left halves of the ventricular septum, whereas 2
of the 3 were diagnosed with subendocardial ischemia on the basis
of exercise testing with thallium-201.
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agnetic resonance
Late gadolinium enhancement on cardiac magnetic resonance
as examined in relationship to subendocardial ischemia in our
CM patients with asymmetric septal hypertrophy [13], showing
hat late gadolinium enhancement as assessed separately in the
ight halves and the left halves of the ventricular septum failed to
rovide useful information for detecting subendocardial ischemia.
ate gadolinium enhancement has been established as the most
eliable noninvasive imaging method for assessing myocar-
ial ﬁbrosis [32,33]. Thus, repetitive subendocardial ischemia is
nlikely to cause myocardial ﬁbrosis in patients with HCM. More
ecently, cardiac magnetic resonance stress testing, for example,
denosine stress perfusion imaging or dobutamine stress wall
otion analysis, has been reported to demonstrate high diagnos-
ic accuracy for the detection of signiﬁcant coronary artery disease
34]. Further studies are needed to clarify whether stress cardiac
agnetic resonance detects subendocardial ischemia in patients
ith HCM.
rognosis
We  prospectively followed 55 patients with nonobstructive
CM for the occurrence of cardiovascular events after the assess-
ent of subendocardial ischemia on exercise scintigraphy [35].
ardiovascular events were deﬁned as sudden death, cardiovas-
ular death, and hospitalization due to heart failure or stroke
ssociated with atrial ﬁbrillation because these 3 modes of death
ere prevalent in patients with HCM [36]. Cardiovascular events
ccurred in 10 of 55 patients during an average follow-up period
f 5.7 years (range, 0.4–7.3 years): 2 patients died suddenly and
 died of stroke; 5 were hospitalized for heart failure and 2 for
troke. The frequency of subendocardial ischemia did not differ
igniﬁcantly between patients with and without cardiovascular
eath (10% versus 3%, p = 0.32) and cardiovascular events (50%
ersus 36%, p = 0.40). Kaplan–Meier event-free rates showed that
ardiovascular events were not related to subendocardial ischemia
Chi-square = 0.56, Log-rank test p = 0.46).
Lack of prognostic value of subendocardial ischemia in our
CM cohort is consistent with our other ﬁnding that subendocar-
ial ischemia was not associated with the presence of gadolinium
nhancement on magnetic resonance imaging [13]; prospective
tudies on HCM demonstrated that the presence of late gadolinium
nhancement is a predictor of adverse events [37,38]. On the other
and, subendocardial ischemia has been reported to be associated
ith elevated LV ﬁlling pressure [6,7] and abnormal blood pressure
esponse to exercise [21,22], possibly leading to poor prognosis.
ulticenter studies with longer follow-up are needed to conﬁrm
he effect of subendocardial ischemia on prognosis in patients with
CM. It should be also noted that a subset of patients with HCM is
nown to have different clinical courses, compared with our cohort
39].
reatment
A major cause of chest symptoms in HCM patients is thought
o be myocardial ischemia [8,40], which results from failure of
he coronary microcirculation due to reduced arteriolar den-
ity, increased oxygen demand of the hypertrophied myocardium,
bnormalities of the small vessels, ﬁbrosis, disarray, or elevated
V end-diastolic pressure, among others [8,9,41]. In our HCM
ohort, the frequency of chest symptoms was signiﬁcantly higher
n patients with subendocardial ischemia than in patients without
t [10,13]. Furthermore, in our study consisting of mostly nonob-
tructive HCM patients, subendocardial ischemia improved in 89%
[
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of patients and disappeared in 67% after the administration of vera-
pamil (240 mg  daily) [42], ﬁndings consistent with a previous study
[6]. We  also showed that diltiazem (120 mg daily) improved both
subendocardial ischemia and chest symptoms in more than 60% of
HCM patients without negatively affecting exercise tolerance [43].
Conclusions
Our experience suggests that subendocardial ischemia is asso-
ciated with various clinical features in patients with HCM. A
diagnosis of subendocardial ischemia may  be helpful in selecting
HCM patients who will beneﬁt from medications to relieve chest
symptoms. The patient described in the introduction of this arti-
cle is likely to suffer from subendocardial ischemia associated with
HCM, which could be treated with appropriate medications.
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